Innovent Biologics, Inc.
IVBXF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $5,953 | $5,470 | $3,952 | $3,505 |
| % Growth | 8.8% | 38.4% | 12.8% | – |
| Cost of Goods Sold | $1,354 | $1,317 | $1,094 | $1,025 |
| Gross Profit | $4,600 | $4,152 | $2,858 | $2,479 |
| % Margin | 77.3% | 75.9% | 72.3% | 70.7% |
| R&D Expenses | $1,009 | $1,282 | $1,399 | $1,305 |
| G&A Expenses | $442 | $418 | $320 | $382 |
| SG&A Expenses | $2,817 | $2,886 | $2,199 | $2,135 |
| Sales & Mktg Exp. | $2,375 | $2,468 | $1,879 | $1,753 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $3,826 | $4,167 | $3,599 | $3,440 |
| Operating Income | $774 | -$15 | -$741 | -$960 |
| % Margin | 13% | -0.3% | -18.7% | -27.4% |
| Other Income/Exp. Net | $124 | $329 | $348 | $72 |
| Pre-Tax Income | $897 | $314 | -$393 | -$888 |
| Tax Expense | $63 | $16 | $0 | $0 |
| Net Income | $834 | $298 | -$393 | -$889 |
| % Margin | 14% | 5.4% | -9.9% | -25.4% |
| EPS | 0.51 | 0.18 | -0.24 | -0.56 |
| % Growth | 183.3% | 175% | 57.1% | – |
| EPS Diluted | 0.49 | 0.18 | -0.24 | -0.56 |
| Weighted Avg Shares Out | 1,703 | 1,667 | 1,623 | 1,580 |
| Weighted Avg Shares Out Dil | 1,695 | 1,632 | 1,623 | 1,584 |
| Supplemental Information | – | – | – | – |
| Interest Income | $129 | $394 | $0 | $403 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $256 | $92 | $183 | $103 |
| EBITDA | $1,030 | -$231 | -$249 | -$742 |
| % Margin | 17.3% | -4.2% | -6.3% | -21.2% |